192 related articles for article (PubMed ID: 35656559)
1. Increasing the Reuse of Protein Non-Naïve Nonhuman Primates in Pharmaceutical Drug Discovery and Development: An Overview and Industry Position on the Challenges and Benefits.
Mattis C; Bratcher N; Burns M; Carosino C; de Zafra C; Fancher RM; Georgi K; Graff C; Hukkanen RR; Johnson C; Lao Y; Lange A; Lee D; Lepherd M; Maguire S; Malisauskas M; Manuel M; Miranda S; Reed L; Santos R; Sayers B; Shaw D; Shuster D
Int J Toxicol; 2022 Aug; 41(4):291-296. PubMed ID: 35656559
[TBL] [Abstract][Full Text] [Related]
2. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
[TBL] [Abstract][Full Text] [Related]
3. An IQ Consortium Perspective on The Scientific Committee on Health, Environmental and Emerging Risks Final Opinion on the Need for Nonhuman Primates in Biomedical Research, Production and Testing of Products and Devices (Update 2017).
Adams K; Clemons D; Impelluso LC; Lee D; Maguire S; Myers A; Petursson C; Schulingkamp R; Trouba K; Wright M
Toxicol Pathol; 2019 Jul; 47(5):649-655. PubMed ID: 31280699
[TBL] [Abstract][Full Text] [Related]
4. FDA and industry collaboration: Identifying opportunities to further reduce reliance on nonhuman primates for nonclinical safety evaluations.
Ackley D; Birkebak J; Blumel J; Bourcier T; de Zafra C; Goodwin A; Halpern W; Herzyk D; Kronenberg S; Mauthe R; Shenton J; Shuey D; Wange RL
Regul Toxicol Pharmacol; 2023 Feb; 138():105327. PubMed ID: 36586472
[TBL] [Abstract][Full Text] [Related]
5. Non-Human Primate Husbandry and Impact on Non-Human Primates Health: Outcomes From an IQ DruSafe/3RS Industrial Benchmark Survey.
Salian-Mehta S; Poling J; Birkebak J; Rensing S; Carosino C; Santos R; West W; Adams K; Orsted K; Fillman-Holliday D; Burns M
Int J Toxicol; 2023; 42(2):111-121. PubMed ID: 36543758
[TBL] [Abstract][Full Text] [Related]
6. Considerations regarding the use of nonhuman primates in assessing safety endpoints for pharmaceuticals.
Brown PC; Wange RL
Regul Toxicol Pharmacol; 2023 Sep; 143():105449. PubMed ID: 37453554
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates.
Chapman K; Pullen N; Coney L; Dempster M; Andrews L; Bajramovic J; Baldrick P; Buckley L; Jacobs A; Hale G; Green C; Ragan I; Robinson V
MAbs; 2009; 1(5):505-16. PubMed ID: 20065651
[TBL] [Abstract][Full Text] [Related]
8. The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
Zabka TS; Burkhardt J; Reagan WJ; Gautier JC; Glaab WE; Guffroy M; Harding J; Brees D; McDuffie E; Ramaiah L; Schultze AE; Smith JD; Wolfreys A; Dalmas DA
Regul Toxicol Pharmacol; 2021 Mar; 120():104857. PubMed ID: 33387566
[TBL] [Abstract][Full Text] [Related]
9. The Use of Minipigs for Preclinical Safety Assessment by the Pharmaceutical Industry: Results of an IQ DruSafe Minipig Survey.
Colleton C; Brewster D; Chester A; Clarke DO; Heining P; Olaharski A; Graziano M
Toxicol Pathol; 2016 Apr; 44(3):458-66. PubMed ID: 27006130
[TBL] [Abstract][Full Text] [Related]
10. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
[TBL] [Abstract][Full Text] [Related]
12. Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective.
Staprans SI; Feinberg MB; Shiver JW; Casimiro DR
Curr Opin HIV AIDS; 2010 Sep; 5(5):377-85. PubMed ID: 20978377
[TBL] [Abstract][Full Text] [Related]
13. Regulatory Forum Opinion Piece
Morgan SJ; Couch J; Guzzie-Peck P; Keller DA; Kemper R; Otieno MA; Schulingkamp RJ; Jones TW
Toxicol Pathol; 2017 Apr; 45(3):372-380. PubMed ID: 28351296
[TBL] [Abstract][Full Text] [Related]
14. Alternative methods for the use of non-human primates in biomedical research.
Burm SM; Prins JB; Langermans J; Bajramovic JJ
ALTEX; 2014; 31(4):520-9. PubMed ID: 25058455
[TBL] [Abstract][Full Text] [Related]
15. Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.
Namdari R; Jones K; Chuang SS; Van Cruchten S; Dincer Z; Downes N; Mikkelsen LF; Harding J; Jäckel S; Jacobsen B; Kinyamu-Akunda J; Lortie A; Mhedhbi S; Mohr S; Schmitt MW; Prior H
Regul Toxicol Pharmacol; 2021 Nov; 126():105029. PubMed ID: 34455009
[TBL] [Abstract][Full Text] [Related]
16. Use of nonhuman primates in research in North America.
Lankau EW; Turner PV; Mullan RJ; Galland GG
J Am Assoc Lab Anim Sci; 2014 May; 53(3):278-82. PubMed ID: 24827570
[TBL] [Abstract][Full Text] [Related]
17. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
Wong H; Bohnert T; Damian-Iordache V; Gibson C; Hsu CP; Krishnatry AS; Liederer BM; Lin J; Lu Q; Mettetal JT; Mudra DR; Nijsen MJMA; Schroeder P; Schuck E; Suryawanshi S; Trapa P; Tsai A; Wang H; Wu F
Drug Discov Today; 2017 Oct; 22(10):1447-1459. PubMed ID: 28476536
[TBL] [Abstract][Full Text] [Related]
18. The SCHER report on non-human primate research - biased and deeply flawed.
Bailey J; Taylor K
Altern Lab Anim; 2009 Sep; 37(4):427-35. PubMed ID: 19807214
[TBL] [Abstract][Full Text] [Related]
19. Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control.
Hariparsad N; Ramsden D; Palamanda J; Dekeyser JG; Fahmi OA; Kenny JR; Einolf H; Mohutsky M; Pardon M; Siu YA; Chen L; Sinz M; Jones B; Walsky R; Dallas S; Balani SK; Zhang G; Buckley D; Tweedie D
Drug Metab Dispos; 2017 Oct; 45(10):1049-1059. PubMed ID: 28646080
[TBL] [Abstract][Full Text] [Related]
20. Reprint of: Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative.
DaSilva JK; Breidenbach L; Deats T; Li D; Treinen K; Dinklo T; Kervyn S; Teuns G; Traebert M; Hempel K
J Pharmacol Toxicol Methods; 2020 Sep; 105():106919. PubMed ID: 33011055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
